Kingdom Therapeutics https://validator.w3.org/feed/docs/rss2.html Kingdom Therapeutics Selects Novotech as CRO for Groundbreaking Autism Clinical Trials Facilitated by 5 Horizons Capital Kingdom Therapeutics Completes Positive Pre-IND Meeting with FDA for KT-20610 Kingdom Key Advisor Highlights UK Potential To Be Global Cannabinoid R&D Leader Review Highlights Intricate Interplay Between The Gut And The Brain  Kingdom Therapeutics Join CRDG Launch Promoting UK Global Leadership In Cannabinoid R&D Kingdom Therapeutics Joins UK Cannabinoid Research & Development Group (CRDG) Home Kingdom Therapeutics Presents Key Data At Major US Autism Conference Newsroom Latest CDC Report Shows Rising Autism Prevalence ‘MicrobeMom’ Research Provides Insights Into Maternal Gut Bacteria New Research Unravels Microbiota’s Impact On Neurodevelopment And Plasticity Kingdom Board Strengthened By The Appointment Of Industry Leader Dr. Jeanne Bolger Multi-level Analysis Sheds Light On Autism-Microbiome Link Pediatric Neurologist Dr John Gaitanis Joins Kingdom Therapeutics’ Scientific Advisory Board Contact Media Enquiries Cookie Declaration Our Science Privacy Policy Leadership Team About Us Board of Directors Our Portfolio